Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why Dentists Should Be Concerned about Superbugs and Antibiotic Resistance

On this episode of HealthFirst Talks, host Dr. Don Cohen, Chief Clinical Officer, HealthFirst, talked with a panel about the concern of superbugs and antibiotic resistance in dentistry. The panel included Dr. Fiona Collins, General Dentist and infection control expert, Dr. Scott Cohen, family physician and clinical informaticist, Dr. Heather Ferrarese, a clinical pharmacist with…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from HealthFirst on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

On this episode of HealthFirst Talks, host Dr. Don Cohen, Chief Clinical Officer, HealthFirst, talked with a panel about the concern of superbugs and antibiotic resistance in dentistry. The panel included Dr. Fiona Collins, General Dentist and infection control expert, Dr. Scott Cohen, family physician and clinical informaticist, Dr. Heather Ferrarese, a clinical pharmacist with a concentration in community pharmacy, and Dr. Stanley Malamed, a dentist anesthesiologist.

This panel discussion was presented at the 2021 OSAP Virtual Conference.

While this panel is about the concern of antibiotic resistance, it’s important to note all the good that they have done, according to Ferrarese. She elaborated that Penicillin was discovered in 1928 by Alexander Fleming, and, since then, antibiotics have become the cornerstone of modern medicine. Along with public sanitation and immunization, antibiotics have significantly contributed to the control of infectious diseases, including doubling the life span in developing countries over the past two centuries. 

However, this doesn’t mean they’re without they’re challenges and negative impacts.

“Antibiotics can cause adverse drug reactions,” Collins said. “One of the particularly worrying ones is actually gastrointestinal infections, in particular C. difficile.”

These bacteria mainly affect older patients in long-term care facilities or hospitals and usually occur after administering antibiotics. It causes a range of symptoms, ranging from diarrhea to life-threatening inflammation of the colon.

The group also dug into how to identify the key risks and concerns with superbugs, offered insight into how to understand the frequency in which antibiotic prescriptions are written and how often they are overprescribed, and highlighted recommendations from the ADA, AHA, and AAOS. Listen to hear more of the group’s chat.

While low-intensity options could be safer, it’s important to understand your space, the specific device and solution you’re looking into, and how to make a space as safe as possible without putting inhabitants in danger.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

HealthFirst

Part of this channel

HealthFirst

Practice-ready solutions for dental and medical offices nationwide.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512